Jump Financial LLC Invests $348,000 in Catalent, Inc. (NYSE:CTLT)

Jump Financial LLC purchased a new position in Catalent, Inc. (NYSE:CTLT) during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 7,735 shares of the company’s stock, valued at approximately $348,000.

Several other hedge funds and other institutional investors have also recently modified their holdings of CTLT. Gladius Capital Management LP purchased a new position in shares of Catalent during the 3rd quarter worth $28,000. GAMMA Investing LLC acquired a new position in Catalent in the 4th quarter valued at about $33,000. Cary Street Partners Investment Advisory LLC boosted its holdings in Catalent by 1,162.3% in the 3rd quarter. Cary Street Partners Investment Advisory LLC now owns 770 shares of the company’s stock valued at $35,000 after purchasing an additional 709 shares during the last quarter. Rakuten Securities Inc. purchased a new stake in shares of Catalent in the 4th quarter valued at approximately $46,000. Finally, Federated Hermes Inc. acquired a new stake in shares of Catalent during the 4th quarter worth approximately $46,000.

Wall Street Analyst Weigh In

Several brokerages recently weighed in on CTLT. Royal Bank of Canada reiterated a “sector perform” rating and issued a $63.50 price objective on shares of Catalent in a research report on Tuesday, February 20th. StockNews.com assumed coverage on shares of Catalent in a research report on Tuesday. They issued a “sell” rating on the stock. UBS Group reiterated a “neutral” rating and set a $63.50 price target (up from $58.00) on shares of Catalent in a research report on Tuesday, February 6th. Finally, Stephens restated an “equal weight” rating and issued a $63.50 price objective on shares of Catalent in a report on Thursday, April 4th. Two analysts have rated the stock with a sell rating, eight have assigned a hold rating and three have issued a buy rating to the company. According to data from MarketBeat, the company has a consensus rating of “Hold” and an average price target of $53.14.

Catalent Trading Up 0.3 %

Shares of NYSE:CTLT opened at $54.79 on Friday. Catalent, Inc. has a 52 week low of $31.80 and a 52 week high of $60.20. The company’s 50 day moving average is $56.02 and its two-hundred day moving average is $50.72. The company has a market cap of $9.92 billion, a PE ratio of -8.98, a P/E/G ratio of 5.90 and a beta of 1.18. The company has a current ratio of 2.51, a quick ratio of 1.77 and a debt-to-equity ratio of 1.37.

Catalent (NYSE:CTLT) last announced its quarterly earnings results on Wednesday, May 8th. The company reported ($0.15) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.21 by ($0.36). Catalent had a negative return on equity of 2.73% and a negative net margin of 26.61%. The business had revenue of $1.07 billion for the quarter, compared to analysts’ expectations of $1.11 billion. Equities analysts predict that Catalent, Inc. will post 0.31 earnings per share for the current fiscal year.

Catalent Profile

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules.